Berry Genomics Co Ltd Asset Resilience Ratio
Berry Genomics Co Ltd asset resilience ratio. Berry Genomics Co Ltd (000710) has an Asset Resilience Ratio of 0.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Berry Genomics Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Berry Genomics Co Ltd (1997–2024)
Asset resilience ratio of Berry Genomics Co Ltd from 1997 to 2024. This chart shows how Berry Genomics Co Ltd's Asset Resilience Ratio has changed over time. Read Berry Genomics Co Ltd (000710) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Berry Genomics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Berry Genomics Co Ltd (000710) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥10.48 Million | 0.45% |
| Total Liquid Assets | CN¥10.48 Million | 0.45% |
Asset Resilience Insights
- Limited Liquidity: Berry Genomics Co Ltd maintains only 0.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Berry Genomics Co Ltd Industry Peers by Asset Resilience Ratio
Compare Berry Genomics Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Berry Genomics Co Ltd Asset Resilience Ratio by Year (1997–2024)
Berry Genomics Co Ltd asset resilience ratio by year from 1997 to 2024. The table below shows the annual Asset Resilience Ratio data for Berry Genomics Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.71% | CN¥17.03 Million ≈ $2.49 Million |
CN¥2.38 Billion ≈ $348.96 Million |
+0.21pp |
| 2023-12-31 | 0.51% | CN¥13.86 Million ≈ $2.03 Million |
CN¥2.74 Billion ≈ $401.12 Million |
+0.36pp |
| 2022-12-31 | 0.14% | CN¥4.51 Million ≈ $659.26K |
CN¥3.20 Billion ≈ $468.39 Million |
+0.03pp |
| 2021-12-31 | 0.11% | CN¥3.81 Million ≈ $558.25K |
CN¥3.52 Billion ≈ $515.05 Million |
-0.01pp |
| 2020-12-31 | 0.12% | CN¥3.81 Million ≈ $558.25K |
CN¥3.24 Billion ≈ $474.69 Million |
-0.09pp |
| 2019-12-31 | 0.21% | CN¥6.43 Million ≈ $940.91K |
CN¥3.07 Billion ≈ $449.07 Million |
-20.04pp |
| 2016-12-31 | 20.25% | CN¥111.00 Million ≈ $16.24 Million |
CN¥548.04 Million ≈ $80.20 Million |
-29.86pp |
| 2015-12-31 | 50.11% | CN¥250.00 Million ≈ $36.58 Million |
CN¥498.88 Million ≈ $73.00 Million |
+48.16pp |
| 1998-12-31 | 1.95% | CN¥6.00 Million ≈ $877.99K |
CN¥307.78 Million ≈ $45.04 Million |
+0.22pp |
| 1997-12-31 | 1.72% | CN¥5.00 Million ≈ $731.66K |
CN¥289.91 Million ≈ $42.42 Million |
-- |
About Berry Genomics Co Ltd
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcri… Read more